| Date | Title | Description | Source |
| 21.11.2023 | MorphoSys with positive phase 3 study results in myelofibros... | MorphoSys AG, Planegg, Germany, announced compelling results from the Phase 3 MANIFEST-2 study evalu... | bio-m.org/... |
| 13.09.2023 | MorphoSys Receives U.S. FDA Fast Track Designation for Tulmi... | MorphoSys AG received the U.S. Food and Drug Administration (FDA) granted Fast Track designation for... | bio-m.org/... |
| 09.01.2023 | MorphoSys AG: MorphoSys Expects Topline Data from Phase 3 St... | MUNICH, GERMANY / ACCESSWIRE / January 9, 2023 / MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced toda... | accesswire... |
| 14.11.2022 | Deep disappointment with MorphoSys' and Roche's Alzheimer's ... | The study results announced today for the Alzheimer's drug Gantenerumab from MorphoSys's license par... | bio-m.org/... |
| 27.10.2022 | MorphoSys Presents Preliminary Results from Phase 1/2 Study ... | The findings, including encouraging preliminary efficacy data in various tumor types, were presented... | accesswire... |
| 29.09.2022 | Aiming for fourth nod, Sarepta files another DMD gene th... | Sarepta Therapeutics has filed the data needed for an FDA accelerated approval, which wou... | endpts.com... |
| 28.07.2022 | MorphoSys AG: Invitation to MorphoSys' Second Quarter and Fi... | Conference Call Alert
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / July 28, 2022 / MorphoSys AG (FSE:... | accesswire... |
| 15.06.2022 | MorphoSys finds a nice, new billion-dollar home for unwanted... | MorphoSys has found a home for a couple of assets it doesn’t want anymore—a nice billion-dollar home... | fiercebiot... |
| 22.03.2022 | MorphoSys and Incyte Announce Swissmedic Temporary Approval ... | MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combinati... | accesswire... |
| 30.11.2021 | MorphoSys AG: Preliminary announcement of the publication of... | DGAP Preliminary announcement financial reports: MorphoSys AG / Preliminary announcement on the disc... | marketscre... |
| 30.11.2021 | MorphoSys AG: Preliminary announcement of the publication of... | DGAP Preliminary announcement financial reports: MorphoSys AG / Preliminary announcement on the disc... | marketscre... |
| 12.11.2021 | MorphoSys AG Reports First Nine Months and Third Quarter 202... | MorphoSys AG Reports First Nine Months and Third Quarter
2021 Results
- Monjuvi U.S. net product s... | marketscre... |
| 11.11.2021 | MorphoSys AG Reports First Nine Months and Third Quarter 202... | DGAP-News: MorphoSys AG / Key word(s): Quarterly / Interim Statement
MorphoSys AG Reports First Nin... | marketscre... |
| 11.11.2021 | PRESS RELEASE : MorphoSys AG Reports First Nine -2- | Research and Development (64.4) (34.2) (88%) (138.2) (86.6) (60%) Selling (32.4) (32.9) (2%) (89.0) ... | marketscre... |
| 10.11.2021 | MorphoSys Announces Departure of Roland Wandeler | DGAP-News: MorphoSys AG / Key word(s): Miscellaneous
MorphoSys Announces Departure of Roland Wandel... | marketscre... |
| 10.11.2021 | MorphoSys Announces Departure of Roland Wandeler | Media Release
MorphoSys Announces Departure of Roland Wandeler
Planegg/Munich, Germany, November 9... | marketscre... |
| 02.11.2021 | MorphoSys AG announces Monjuvi(R) Sales for the First Nine M... | Media Release
Planegg/Munich, Germany, November 02, 2021
MorphoSys AG announces Monjuvi® Sales for... | marketscre... |
| 02.11.2021 | MorphoSys AG announces Monjuvi(R) Sales for the First Nine M... | DGAP-News: MorphoSys AG / Key word(s): 9 Month figures
MorphoSys AG announces Monjuvi(R) Sales for ... | marketscre... |
| 29.07.2021 | MorphoSys : Reports Second Quarter and First Half 2021 Resul... | MorphoSys AG Reports Second Quarter and First Half
2021 Results
- Monjuvi U.S. net product sales o... | marketscre... |
| 28.07.2021 | MorphoSys : Reports Second Quarter and First Half 2021 Resul... | DGAP-News: MorphoSys AG / Key word(s): Half Year Results
MorphoSys AG Reports Second Quarter and Fi... | marketscre... |
| 26.07.2021 | Ad-hoc: MorphoSys AG to update financial guidance for 2021 a... | Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No 596/2... | marketscre... |
| 15.07.2021 | MorphoSys : to Complete Transformational Acquisition of Cons... | DGAP-News: MorphoSys AG / Key word(s): Mergers & Acquisitions
MorphoSys to Complete Transformat... | marketscre... |
| 04.06.2021 | MorphoSys to Buy Constellation Pharmaceuticals, for $1.7 Bil... | MorphoSys AG (FSE: MOR; NASDAQ: MOR), a near Munich, Germany-based commercial-stage biopharmaceutica... | finsmes.co... |
| 03.06.2021 | CONSTELLATION PHARMACEUTICALS, INC.
Constellation Pharmaceu... | MorphoSys to Acquire Constellation Pharmaceuticals
Accelerates Growth Strategy by Adding Two Mid- t... | marketscre... |
| 02.06.2021 | MORPHOSYS AG
MorphoSys : to Acquire Constellation Pharmaceu... | Ad hoc release according to article 17 para. 1 MAR
Planegg/Munich, Germany and Cambridge, Mass., Ju... | marketscre... |
| 02.06.2021 | MORPHOSYS AG
MorphoSys : to Acquire Constellation Pharmaceu... | DGAP-News: MorphoSys AG / Key word(s): Mergers & Acquisitions
MorphoSys to Acquire Constellatio... | marketscre... |
| 02.06.2021 | MORPHOSYS AG
MorphoSys : to Acquire Constellation Pharmaceu... | DGAP-Ad-hoc: MorphoSys AG / Key word(s): Mergers & Acquisitions
MorphoSys AG to Acquire Constel... | marketscre... |
| 02.06.2021 | MORPHOSYS AG
PRESS RELEASE : MorphoSys to Acquire Constella... | MorphoSys will host a conference call and webcast to discuss the transaction on June 2, 2021 at 2:00... | marketscre... |
| 02.06.2021 | MORPHOSYS AG
PRESS RELEASE: MorphoSys to Acquire Constellat... | MorphoSys will host a conference call and webcast to discuss the transaction on June 2, 2021 at 2:00... | marketscre... |
| 19.03.2021 | MORPHOSYS AG
MorphoSys : Financial Statements 2020 of Morph... | Financial Statements of MorphoSys AG as of December 31, 2020
MorphoSys AG, Planegg
2
3
Managemen... | marketscre... |
| 19.03.2021 | MorphoSys : Financial Statements 2020 of MorphoSys AG (Germa... | Financial Statements of MorphoSys AG as of December 31, 2020
MorphoSys AG, Planegg
2
3
Managemen... | marketscre... |
| 25.01.2021 | I-Mab and MorphoSys Announce First Patient Dosed in U.S. Pha... |
SHANGHAI, China and PLANEGG/MUNICH, Germany, Jan. 25, 2021 /PRNewswire/ -- I-Mab (Nasdaq: IMAB), a... | prnewswire... |
| 03.08.2020 | FDA approves MorphoSys, Incyte’s drug for vulnerable lymphom... | Shares of MorphoSys were up more than 5% premarket on the Nasdaq Monday morning. Shares of Incyte we... | medcitynew... |
| 14.01.2020 | Incyte pays MorphoSys $750M upfront in lymphoma drug partner... | Under the deal, both companies will develop and commercialize tafasitamab in the U.S., while Incyte ... | medcitynew... |
| 30.12.2019 | MorphoSys files for approval of drug for hard-to-treat lymph... | “The BLA submission marks a significant milestone in MorphoSys’ history and demonstrates our dedicat... | medcitynew... |
| 25.06.2019 | SQZ, Erytech kick off $57M cell therapy partnership; Je... | → In a marriage of two technologies meant to make cell therapies more powerful, SQZ Biotech i... | endpts.com... |
| 19.02.2019 | AbbVie scores speedy review for RA drug upadacitinib; M... | → AbbVie $ABBV has high hopes, projecting peak potential sales of $6.5 billion, for its oral... | endpts.com... |
| 08.02.2019 | MorphoSys taps Bavencio lead for US operations; Two top... | → Having built out a commercial footprint in the US and led the launch of Bavencio for Merck K... | endpts.com... |
| 05.02.2019 | Sanofi reports positive data for myeloma drug isatuximab, bu... | The study enrolled 307 patients in 24 countries, who were randomized to receive Celgene’s Pomalyst (... | medcitynew... |
| 09.04.2018 | Term Sheet — Monday, April 9 | BIG PLAYS
Good morning, Term Sheet readers.
Paid Content What you need to know about growing cyber... | fortune.co... |
| 23.03.2018 | MorphoSys seeks $150M IPO to fund late-phase anticancer push | MorphoSys has filed to raise $150 million in a Nasdaq IPO. The listing will enable MorphoSys to pump... | fiercebiot... |
| 07.03.2017 | Roche is bringing back gantenerumab from the dead, takin... | Marlies Sproll, MorphoSys
Alzheimer’s drugs are expensive to test and unlikely to succeed, ... | endpts.com... |
| 17.11.2016 | J&J takes one of its top blockbuster prospects to the F... | MorphoSys CSO Marlies Sproll
Hot on the heels of a new round of Phase III data showing that th... | endpts.com... |
| 10.08.2015 | MorphoSys and G7 Therapeutics sign alliance |
MorphoSys AG and Zurich-based start-up G7 Therapeutics AG have announced an agreement to collabora... | startuptic... |
| - | FDA approves MorphoSys, Incyte’s drug for vulnerable lymphom... | The Food and Drug Administration has approved a new drug for patients with an aggressive form of lym... | medcitynew... |
| - | Incyte pays MorphoSys $750M upfront in lymphoma drug partner... | A German biotech company developing a drug for blood cancers has signed a development and commercial... | medcitynew... |
| - | MorphoSys files for approval of drug for hard-to-treat lymph... | A German biotech company hopes to win approval for a drug developed especially for certain lymphoma ... | medcitynew... |
| - | Sanofi reports positive data for myeloma drug isatuximab, bu... | A drug under development for the blood cancer multiple myeloma has posted positive Phase III data, i... | medcitynew... |
